Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research

Press Release

Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export

VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to report a significant update to its collaboration with The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV).

Primary Sponsors

Get Connected

Karma Koala Podcast

Top Marijuana Blog